September 1, 2022
Greg Duncan joined the CorMedix board in November 2020. Greg currently serves as the Chairman and CEO of Virios Therapeutics, a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Prior to joining his current company in 2020, Greg served as President and CEO of Celtaxsys, a privately held biotechnology company focused on cystic fibrosis and other rare, inflammatory diseases. Greg spent the majority of his career in senior leadership roles in commercial stage pharmaceutical companies, including UCB, where his roles included serving as President of its North America business. In addition to acting on the executive committee and guiding the strategic direction for the company’s specialty biopharma business, Greg was responsible for managing a multi-billion dollar global business and overseeing the launches of multiple new products. Prior to his roles with UCB, Greg spent approximately 18 years at Pfizer where he gained significant experience across sales and marketing functions including serving as SVP of US Marketing and later as President of Pfizer’s Latin America business. Greg received his undergraduate degree from the State University of New York, Albany, and earned an MBA degree from Emory University.